Clinical trial
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo…
NCT02425891 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02425891 |
|---|---|
| Title | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) |
| Official title | A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Triple Negative Breast Cancer |
| Intervention type | Drug |
| Interventions | Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-Paclitaxel, Placebo |
| Enrollment | 902 |
| Start date | Jun 23, 2015 |
| Primary completion | Apr 14, 2020 |
| Completion | Aug 31, 2021 |
| First posted | Apr 24, 2015 |
| Last update posted | Jul 19, 2022 |
| Countries | Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, Colombia, Costa Rica, Czechia, Estonia and 28 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: